{"links":{"html":"https://www.erudio.com/reports/xmab819-01-nct05433142","json":"https://www.erudio.com/reports/xmab819-01-nct05433142.json","markdown":"https://www.erudio.com/reports/xmab819-01-nct05433142.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"xmab819-01-05433142"}},"request":"https://www.erudio.com/contact?report=xmab819-01-05433142"},"offer":{"cited_commentary_sources":15,"verified_hcp_statements":29,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"xmab819-01-nct05433142"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=xmab819-01-05433142","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/xmab819-01-nct05433142","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T07:52:47.809343Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Incidence of dose limiting toxicities (DLTs)"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":8,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":4,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":10,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":7,"title":"High-dose evidence and small-sample uncertainty"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":7,"title":"Mechanistic differentiation and the proposed late-line therapeutic role"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":4,"title":"Prospective development and regulatory expectations"}],"counts":{"cited_sources":15,"claims_by_expression_type":{"interpretation":7,"opinion":8,"question":1,"restatement":11,"uncertainty":1,"unspecified":1},"claims_by_kind":{"source_observation":29},"clinician_statements":18,"evidence_units":19,"findings":4,"organisational_accounts":3,"people_cited":10,"people_identity_verified":9,"people_total":10,"screened_sources":24,"verified_claims":29},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":7},"has_counterview":false,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":6,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"A differentiated mechanism attracts interest, but becoming a therapeutic pillar remains a question"},{"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":6,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":8,"passages":8,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Dose-dependent activity supports development, but the high-dose estimate is not confirmation"},{"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":6,"views":3},"has_counterview":true,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":10,"passages":10,"sources":10,"sources_by_kind":{"commentary":10}},"title":"Manageable toxicity descriptions coexist with substantial adverse-event burden and a management learning need"},{"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Regulatory ambition is a reported prospect, not an achieved development milestone"}],"medical_affairs_question":"What durability, safety burden and confirmatory evidence would make this mechanism clinically meaningful after existing therapies?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A differentiated mechanism, with durability and safety still unresolved"},{"id":"section-2","level":2,"title":"Dose response encourages development, but cohort scope changes the reading"},{"id":"section-3","level":2,"title":"Manageability does not erase the toxicity burden"},{"id":"section-4","level":2,"title":"Development support is not regulatory confirmation"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, sequential, phase1","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":1}],"id":"T1","label":"Primary endpoint: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)"},{"findings":[],"id":"T2","label":"Primary endpoint: Incidence of dose limiting toxicities (DLTs)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":4}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":10}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T07:52:47.809343Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T08:05:16Z","record_hash":"cdd30487915c4fdb4d36e60f82a956fd6f4a3cb0bb3480c71829ed9ca00401c9","release_hash":"207a5fb68da2dad48016f08cd4337267502203f25207dc2de00d512b46f86c10","report_id":"erudio-nct05433142","run_id":"c70b0ba6-0ea4-48ac-adbc-444fe52eb906","schema_version":"5.0","slug":"xmab819-01-05433142","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"XmAb819-01 examines the safety and tolerability of XmAb819 in relapsed or refractory clear-cell kidney cancer. One X poster supports continued development; a therapeutic role remains an open question in an X post. A differentiated mechanism attracts interest from an X poster, while an X post highlights a toxicity-management learning need. Confirmation of the high-dose signal remains questioned in an X post. The sources reviewed for this edition place the trial’s main results at ESMO 2026.","meta_description":"24 sources screened · 29 verified statements (18 from clinicians verified by NPI or staff page) from 15 sources · 4 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-64f448437dfd96b7abdf"],"id":"F2","paraphrase":"An X post addresses the question of what evidence would establish confirmation of the high-dose activity signal.","publication_caveats":["The poster’s individual identity and clinical role are not confirmed in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2026-10-26","title":"Dose-dependent activity supports development, but the high-dose estimate is not confirmation"}]},"publication":{"approved_at":"2026-10-29T08:05:16Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":24},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on treatment activity after prior therapy and continued treatment among responders in heavily pretreated clear cell renal cell carcinoma.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational reports, analyst assessments and reposts must not be counted as independent clinician endorsements.","Some discussions were only partly assessed, and 52 additional sources without an explicit trial-name mention were not read. Relevant discussion using unnamed references or different transcription variants may be missing.","Several posts discuss XmAb819 or its phase 1 ccRCC setting without identifying NCT05433142. Their observations remain attributed contextual reports rather than independently identifier-confirmed results.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No full protocol, results publication for NCT05433142 or XmAb819 regulatory label was available in the sources reviewed. The reported efficacy, toxicity and development assertions cannot be reconciled against those documents here.","Different cohort scopes, adverse-event categories and cutoff descriptions prevent combining the reported figures into one efficacy or safety estimate. Treatment persistence does not establish mature duration of response.","The a speaker post is dated November 2025, whereas the other cited commentary is dated October 2026. Post dates do not establish readout dates, longitudinal changes of view or direct disagreement."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":15},"count":15,"evidence_window":{"end":"2026-10-27","start":"2025-11-20"},"retrieval_snapshot":"2026-10-29T07:19:40.567233Z","timeline":[{"count":1,"week":"2025-W47"},{"count":11,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05433142:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05433142:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mmq2caobcgxv5mmlcomg5fpr-3myoss2w6db2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945440300526178528:1f735bcc-32df-4a5e-adcb-c909903590f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1945921260086599831:2290cf22-2701-48a9-bd6f-c7526bcfeb32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991557914893644032:302fc087-9d28-4f99-b155-b3e1a6c9ad7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080315115224613060:e2a050a6-52f9-4e6c-bd25-f1a26443c6df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113670786502262917:7a7749e6-4214-47d8-bdde-946b6e229207","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114273857095844239:22242b90-7c89-42f5-9f2f-7832a03baf24","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114274715481071873:69f012fd-3a31-4c19-b97e-8665e1eab33c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114275046814327226:5b8de29d-b252-4b52-bdb8-91c96930adb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114275487367209067:9a0d3a56-37b0-43fe-b364-d4fa960c7076","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114276286520611267:3435b9fb-8547-4cc0-8217-f50168da8930","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114276288869384603:db9ea333-0a40-4adf-8d7c-4cf7bdc9287c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114276379877630453:de0f95c3-78f2-4771-98cf-29375da8b8a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114280635724353705:8f3c9d5d-be7c-40ee-b26e-bdfbd600aa78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114292267854811361:9888aee7-ede2-4a90-a425-d529e06c2f5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114296916729098749:a6dd70a9-85f9-4c9a-83a9-6fbb74fed693","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114318720474521631:c8afdc4b-a08d-48cf-b432-e0b361da6be9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114386586733273492:cc85c503-cbcf-451a-a127-fefeb40c8aef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114561540615766321:6cfea4df-7774-4d23-953a-b5818f95247f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114608147981565972:5f90cf89-76e3-4251-a02f-24aee4d7ad4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114762903861485620:f9d9083f-8695-4360-b2af-3ffe8c8b97f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114767074077675845:62bd6054-881d-4406-bd83-17e16b387814","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114821563681759476:01c8e803-a9de-459f-ad41-0268645e2912","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115045160509927891:9205f095-9c91-466a-9a5f-d9cbea0384ba","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":24},"count":24,"evidence_window":{"end":"2026-10-27","start":"2025-07-16"},"retrieval_snapshot":"2026-10-29T07:19:40.567233Z","timeline":[{"count":2,"week":"2025-W29"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W30"},{"count":14,"week":"2026-W43"},{"count":6,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: xmab819","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Clear Cell Renal Cell Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"XmAb819-01","aliases":["XmAb819-01","Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma","A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma"],"brief_title":"Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":307,"type":"ESTIMATED"},"interventions":[{"name":"XmAb819","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"}],"nct_id":"NCT05433142","official_title":"A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma","overall_status":"RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-02","type":"ESTIMATED"},"primary_endpoints":[{"description":"Safety and tolerability as assessed by incidence of TEAEs; incidence of clinically significant changes in safety laboratory tests, PE findings, vital signs, and ECGs; incidence and severity of CRS","measure":"Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819)","timeFrame":"28 days"},{"description":"Safety and tolerability as assessed by incidence of DLTs and all available data which will be used to determine the optimal dose regimen.","measure":"Incidence of dose limiting toxicities (DLTs)","timeFrame":"28 days"}],"registered_date":{"date":"2022-06-27","type":"ACTUAL"},"registry_last_updated":"2026-08-03","registry_url":"https://clinicaltrials.gov/study/NCT05433142","short_name":"XmAb819-01","short_name_basis":"canonical_name","sponsor":"Xencor, Inc.","start_date":{"date":"2022-06-13","type":"ACTUAL"},"study_design":"interventional, na, sequential, phase1","study_ids":[{"id":"XmAb819-01","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}